2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-117147
    GSK2945 1438071-12-5 98%
    GSK2945 is a class of tertiary amine, and is a highly specific Rev-erbα/REV-ERBα (mouse/human reverse erythroblastosis virus α) antagonist with EC50s of 21.5 μM and 20.8 μM, respectively. GSK2945 enhances cholesterol 7α-hydroxylase (CYP7A1) level and cholesterol metabolism.
    GSK2945
  • HY-117702
    RB 101 135949-60-9 98%
    RB 101 is a blood-brain barrier-crossing prodrug as well as aminopeptidase N and neutral endopeptidase-24.11 inhibitor. RB 101 blocks enkephalin breakdown, elevates extracellular enkephalin levels and activate δ-opioid receptor and dopamine D1 receptor. RB 101 can be used for the research of pain, depressive syndromes, and diabetic neuropathy.
    RB 101
  • HY-117861
    ML198 1380716-06-2 98.0%
    ML198 is a glucocerebrosidase (GCase) modulator with an EC50 of 0.4 μM. ML198 is an activator and non-inhibitory chaperone of glucocerebrosidase. ML198 can be used for the research of Gaucher disease. ML198 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    ML198
  • HY-118040
    3-Oxo-C16:1 1269663-80-0 99.9%
    3-Oxo-C16:1 could induce changes in root protein production in the model legume Medicago truncatula. 3-Oxo-C16:1 is an unsaturated 16-carbon AHL utilized by species such as S. meliloti and Agrobacterium vitus.
    3-Oxo-C16:1
  • HY-118152
    Org-12962 132834-56-1 ≥98.0%
    Org-12962 is a potent, selective and brain-penetrant and 5-HT2C receptor agonist with a pEC50 value of 7.01. Org-12962 also exhibits high effacy for the 5-HT2A and 5-HT2B receptor with pEC50s of 6.38 and 6.28, respectively.Org-12962 displays antiaversive effects in a rat model of panic-like anxiety.
    Org-12962
  • HY-118167
    Monoethylglycinexylidide 7728-40-7 99.69%
    Monoethylglycinexylidide is a metabolite of Lidocain (HY-B0185) via oxidative N-deethylation of Lignocaine by liver cytochrome P-450 enzymes in the liver[1].
    Monoethylglycinexylidide
  • HY-118486
    LDL-IN-1 615264-52-3 99.0%
    LDL-IN-1 (Compound 1) is an antioxidant, and is active against copper mediated LDL oxidation (IC50 = 52 μM). LDL-IN-1 is also an Acyl-CoA:cholesterol acyltransferase-1 and -2 (ACAT-1/2) inhibitor, with IC50s of 60 μM. LDL-IN-1 can be used for anti-atherosclerotic research.
    LDL-IN-1
  • HY-118634
    trans-Resveratrol-4'-O-D-Glucuronide 387372-20-5 99.4%
    Trans-Resveratrol-4'-O-D-Glucuronide (R-4G) is a metabolite of resveratrol with anti-fat accumulation property, and can be used for metabolic research.
    trans-Resveratrol-4'-O-D-Glucuronide
  • HY-119203
    NNC 38-1049 757183-18-9 99.84%
    NNC 38-1049 is an orally active, potent and competitive histamine H3 receptor antagonist. NNC 38-1049 produced an increase in extracellular levels of histamine in the paraventricular nucleus. NNC 38-1049 decreases food intake and body weight, which is promising for research of obesity.
    NNC 38-1049
  • HY-120496
    Clofutriben 1204178-50-6 98%
    Clofutriben (ASP3662) is a selective, orally active and brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor with Ki values of 5.3 nM (human), 2.6 nM (mouse), and 23 nM (rat). Clofutriben inhibits conversion of inactive glucocorticoids to active glucocorticoids, reducing intracellular glucocorticoid exposure. Clofutriben ameliorates neuropathic pain, and restores muscle pressure thresholds in rodent models, while lacking effects in inflammatory pain.
    Clofutriben
  • HY-120851
    O-7460 1572051-31-0
    O-7460 is a potent and selective DAGLα inhibitor, with an IC50 of 0.69 μM. O-7460 shows selectivity over onoacylglycerol lipase (MAGL), human CB1 and CB2 cannabinoid receptors. O-7460 can decrease HFD-caused an up-regulation of 2-AG levels.
    O-7460
  • HY-120891
    trans-EKODE-(E)-Ib 478931-82-7 99.9%
    trans-EKODE-(E)-Ib is a biologically active peroxidation product of linoleic acid.
    trans-EKODE-(E)-Ib
  • HY-120904
    AMPK-IN-1 1219739-95-3
    AMPK-IN-1 is an activator of AMPK (EC50: 551 nM for isoform α2β2γ1). AMPK-IN-1 leads to eEF2 phosphorylation in a mTORC1-independent way.
    AMPK-IN-1
  • HY-121755
    Tibric acid 37087-94-8 98%
    Tibric acid (CP 18524) has similar effects to those of hypolipidemic agents. Tibric acid has orally active triglyceride-lowering effects. Tibric acid can be used for research of hypertriglyceridemia.
    Tibric acid
  • HY-121827
    LH21 611207-11-5 99.83%
    LH-21 is a potent in vivo neutral cannabinoid CB1 receptor antagonist. LH-21 reduces food intake and body weight gain in obese Zucker rats. , and displays efficacy as a feeding inhibitor.
    LH21
  • HY-121845
    4-Br-Bnlm 1654775-71-9 99.46%
    4-Br-Bnlm is a selective inhibitor of glucose-regulated protein 94 (Grp94) with an EC50 value of 0.96 µM. 4-Br-Bnlm reduces the levels of mutant myocilin proteins as well as wild-type myocilin misfold in cells. 4-Br-Bnlm promotes the clearance of toxic formsof myocilin and reduces myocilin toxicity.
    4-Br-Bnlm
  • HY-12191A
    A 331440 hydrochloride 1049740-32-0 98.01%
    A 331440 hydrochloride is a histamine H3 receptor antagonist. A 331440 hydrochloride binds potently and selectively to human and rat histamine H3 receptors (Ki≤25 nM). A 331440 hydrochloride can be used for antiobesity research.
    A 331440 hydrochloride
  • HY-121989
    cis-Trismethoxy resveratrol 94608-23-8 99.87%
    cis-Trismethoxy resveratrol ((Z)-3,5,4'-Trimethoxystilbene) is an anti-HCV agent and Tubulin inhibitor, with an IC50 of 4 μM against Tubulin. cis-Trismethoxy resveratrol induces G2/M phase cell cycle arrest, reduces DCLK1, decreases CDK1 levels, blocks phosphorylation of Akt Ser473, and induces the expression of p21Cip1/Waf1. cis-Trismethoxy resveratrol exhibits anti-tumor and hepatoprotective activities. cis-Trismethoxy resveratrol can be used in studies related to colon adenocarcinoma, hepatocellular carcinoma, hepatitis C, and liver injury.
    cis-Trismethoxy resveratrol
  • HY-122028
    HSD-016 946396-92-5 99.95%
    HSD-016 is a potent, selective and orally active 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor with IC50 values of 11, 1 and 8 nM against human, mouse and rat 11β-HSD1, respectively. HSD-016 can be used for type 2 diabetes research.
    HSD-016
  • HY-122052
    UK‑396082 400044-47-5 99.89%
    UK‑396082 is a potent thrombin activated fibrinolytic inhibitor (TAFI) inhibitor. UK‑396082 increases plasmin activity and induces a parallel decrease in ECM levels. UK‑396082 can be used in research of chronic kidney disease (CKD).
    UK‑396082
Cat. No. Product Name / Synonyms Application Reactivity